Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Current assets:
Cash and cash equivalents	$ 226,734	$ 156,074
Prepaid expenses and other current assets	8,693	10,194
Income tax receivable	331	524
Total current assets	235,758	166,792
Property and equipment, net	2,057	2,071
Operating lease right-of-use asset	9,181
Other assets	3,877	4,114
Total assets	250,873	172,977
Current liabilities:
Accounts payable	10,004	11,019
Interest payable	758	1,077
Accrued expenses	46,258	53,614
Operating lease liability	813
Due to Roivant Sciences Ltd. (RSL), Roivant Sciences, Inc. (RSI) and Roivant Sciences GmbH (RSG)	196	121
Current maturities of long-term debt	10,867	6,142
Total current liabilities	68,896	71,973
Deferred rent	0	1,157
Deferred interest payable	3,790	2,273
Long-term operating lease liability	9,550
Long-term debt, less current maturities	89,070	93,240
Total liabilities	171,306	168,643
Commitments and contingencies (Note 11)
Shareholders’ equity:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 89,622,626 and 72,057,490 issued and outstanding at June 30, 2019 and March 31, 2019, respectively	2	1
Additional paid-in capital	649,806	505,851
Accumulated other comprehensive (loss) income	(312)	507
Accumulated deficit	(569,929)	(502,025)
Total shareholders’ equity	79,567	4,334
Total liabilities and shareholders’ equity	$ 250,873	$ 172,977